Pulmonary Arterial Hypertension (PAH) Market 2021 with Global Industry Size, SWOT Analysis, Recent Trends, Demand and Share Estimation by 2025 with Top Countries Data

REPORT HIGHLIGHT

The pulmonary arterial hypertension (PAH) market is estimated to represent a global market of USD 5.38 billion by 2017 with growth rate of 5.6%.

Market Dynamics

According to the World Health Organization (WHO), pulmonary arterial hypertension is a debilitating condition, characterized by the elevated pulmonary vascular resistance and pulmonary arterial pressure. The condition may lead to the failure of right ventricular or patient’s death. PAH can be hereditable, idiopathic, or associated with conditions such as congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAH is categorized under rate disease as the prevalence of this disorder is very low, with an estimated prevalence around 15 to 50 cases per million population. However, the prevalence of this disorder is increasing during the past few years owing to the risk factors such as smoking, tobacco consumption, sedentary lifestyle, and other idiopathic conditions.

Download  Sample of This Strategic Report-https://www.kennethresearch.com/sample-request-10293910

The market for Pulmonary Arterial Hypertension is primarily driven by the favourable government initiatives for the development of orphan drugs. The government provides benefits in terms of enhanced patent protection term, tax incentives etc. Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are the two important acts which facilitate the distribution and ethical usage of orphan therapeutics. For instance, The ODA facilitates tax credits up to 50.0% of overall research cost, protocol assistance, waiver in U.S. FDA fees and clinical tax incentives. This fact would, in turn, encourage key players to invest in this industry, augmenting the market growth to great extent.

Furthermore, growing awareness coupled with a well-planned reimbursement structure resulted in superlative diagnosis rate for PAH conditions across the globe, driving the industry growth. However, patent expiry of blockbuster therapeutics pulls back the industry growth to some extent. For instance, drugs such as Uptravi (2023), Orenitram (2024), and Opsumit are expired in near future. Additionally, this condition is often not diagnosed in a timely manner owing to its symptoms are subtle, and is confused with many other disease conditions. This fact would, in turn, further reduce the number of patients undergoing PAH treatment, hampering the market growth to some extent.

Drug Class Takeaway

In terms of drug class, the industry is categorized as Prostacyclin and Analogs, Soluble Guanylyl Cyclase (SGC) Stimulators, Endothelin receptor antagonist (ERA) and Phosphodiesterase-5. An ERA dominated the market with a substantial share of over 40% throughout the study period. On another hand, drugs targeting the prostacyclin pathway reported global sales of over USD 2.3 billion in 2017. Iloprost (Ventavis from Actelion), Epoprostenol (Veletri from Actelion and Flolan from GSK), Treprostinil (Tyvaso, Remodulin, and Orenitram from United Therapeutics) are some of the prostacyclin analogs approved by the U.S. FDA for the treatment of PAH. SGC stimulators are the lowest revenue generating drug class owing to the availability of other effective therapeutics.

Global Pulmonary Arterial Hypertension Market, by Drug Class, 2017 vs 2025

Regional Takeaway

Geographically, the industry is categorized into North America, Europe, Asia Pacific and Rest of the World. Developed regions such as North America and Europe accounted for the highest share of the global market.

Request For Full Report-https://www.kennethresearch.com/sample-request-10293910

Key Vendor Takeaway

Companies such as Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer, and Merck are some of the prominent participants in the global Pulmonary Arterial Hypertension market. Apart of it, the presence of small players is noticeable too. For instance, Actelion Pharmaceuticals is developing a Macitentan drug for pediatric PAH. The company has initiated phase III (titled as “Tomorrow”) study which will evaluate the effect of macitentan on children with PAH. Also, in October 2015, Gilead Sciences, Inc.’s new combination treatment of Tadalafil and Letairis is approved by the U.S. FDA. Such facts will further help key players to enhance their market presence.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2014 & 2016

Base Year – 2017

Estimated Year – 2018

Projected Year – 2025

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY DRUG CLASS

Prostacyclin and Analogs

Soluble Guanylyl Cyclase (SGC) Stimulators

Endothelin receptor antagonist (ERA)

Phosphodiesterase-5

MARKET, BY REGION

North America

U.S.

Canada

Europe

Germany

France

Rest of Europe

Asia Pacific

India

China

Rest of APAC

Rest of the World

Middle East and Africa

Latin America

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Name: Kenneth research

Email:sales@kennethresearch.com

Phone: +1 313 462 0609

Comments

Post a Comment

Popular posts from this blog

Hormone Replacement Therapy (HRT) Market 2021, Top Leading Countries, Companies, Consumption, Drivers, Trends, Forces Analysis, Revenue, Challenges and Global Forecast 2025

REPORT HIGHLIGHT The Hormone Replacement Therapy (HRT) market is estimated to represent a global market of USD 15.8 billion by 2017 with growth rate of 7.5%. Market Dynamics Menopause is a natural and inevitable event, defined as the final menstrual period. It requires a retrospective clinical diagnosis with ethnic and regional variations. Hormone replacement therapies (HRT) such as systemic estrogen (skin patch, gel, or cream) are considered to be the most effective treatment option in the treatment of menopausal night sweats and hot flashes. These therapies also ease vaginal symptoms of menopause such as itching, burning, and dryness. Due to this fact, women undergoing these therapies has increased considerably over the past few years. Download  Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10293918 As per the Rose Research Survey (April 2014), women accepting HT therapy has increased considerably, from 4.5 million in 2005 to around 5.0 million in 2
Read more

FOG Computing Market Size, Share, Trends 2022 Global Industry Key Strategies, Growth, Top Manufacturers, Application, Technology, and Opportunities Forecast to 2031

  Kenneth Research, in its repository of market research reports, have recently added a report on  FOG Computing Market  which emphasizes on the latest trends, key opportunities, drivers, and the challenges associated with the growth of the market during the forecast period, i.e., 2022-2031. U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a
Read more

Poultry Diagnostics Market 2021 Size with Global Demand Analysis and Business Opportunities Outlook 2025

REPORT HIGHLIGHT The Poultry Diagnostics market is estimated to represent a global market of USD 356.9 million by 2017 with growth rate of 8.3%. Market Dynamics Poultry disease outbreak is the prime factor responsible for significant growth of the poultry diagnostics market . For instance, the World Organisation for Animal Health (OIE)’s data stated that in July 2017, Vietnam reported the outbreak of highly pathogenic bird flu H5N1 strains. As per this data, the virus has affected more than 1,140 birds and has killed 300 birds. Moreover, recently in June 2017, an outbreak of H5N8 influenza virus was observed. These outbreaks have created steep demand for diagnostic services across the globe. Download  Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10293913 Thereby, companies and private organizations are actively engaged in developing effective solutions to cure poultry diseases. For instance, MediLabSecure, a laboratory network project, was established
Read more